Compare CoTherix vs Cryptopharma
Customers evaluate the quality of CoTherix's products using the following success metrics.
Overview
CoTherix is 24 yrs old and is based in United States.
CoTherix is dedicated to the development and commercialization of improved therapies for inflammatory lung diseases. The company was formed in 2000 with the initial focus of commercializing a decade of work performed at Columbia University by Gerard Turino, M.D., past president of the American Thoracic Society and chairman of the American Lung Association's Scientific Advisory Council, and Jerome Cantor, M.D., a leading pulmonary pathologist and expert on models of lung disease. Studies conducted by Drs. Turino and Cantor in models of emphysema demonstrated the ability of hyaluronic acid (HA) to protect lung tissue from damage associated with inflammatory lung disease.
Cryptopharma is based in Australia
Cryptopharma is a Company focused on the discovery and development of anti-inflammatory therapeutic agents for treatment of pulmonary diseases. The company's initial focus is on the development of CP92, a treatment of Cystic Fibrosis. Second generation compounds are in development with the potential to treat other inflammatory conditions including asthma and chronic obstructive pulmonary disease (COPD). See www.cryptopharma.com
Demo Video
Leadership
Benson M Fong (Senior Vice President)
David Crump (Chief Executive Officer)
Investors
Actelion, Spray Venture Partners
GBS Venture Partners, UniSeed
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because CoTherix has not claimed their profile.
Work for CoTherix? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for CoTherix?
Claim your profile now.
Information not available because Cryptopharma has not claimed their profile.
Work for Cryptopharma? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Cryptopharma?
Claim your profile now.